Study identifies placental growth factor as a biomarker for vascular cognitive impairment

NewsGuard 100/100 Score

Measuring a key blood molecule may help doctors diagnose whether or how much impaired blood flow to a patient's brain is contributing to dementia or cognitive problems, according to a new study led by a UCLA Health researcher.

Cerebral small vessel disease, a common disease marked by damage to the cells lining the blood vessels in the brain, is a major driver of cognitive problems and dementia in older adults. However, it can be difficult for doctors to determine whether a patient's cognitive impairments stem predominately from Alzheimer's disease or vascular problems, the two most common causes of dementia. Doctors typically rely on MRIs or CAT scans to detect evidence of brain injury to help make that determination, but a certain amount of guesswork is involved.

In new research published Feb. 23 in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, researchers found that patients with higher levels of placental growth factor (PlGF) – a key molecule involved in the formation of new blood vessels, or angiogenesis – were more likely to have cognitive impairment or evidence of brain injury.

Historically, diagnostic studies for cognitive impairment and dementia have been limited to structural brain imaging, but increasingly there's a recognition that we can use the bloodstream as an available but imperfect tool to understand who maximally benefits from those structural and functional imaging tools. It may also tell us who might be the best candidates for some of the really new emerging drugs that are available on the market to treat cognitive impairment and dementia."

Jason Hinman, MD, PhD, study's lead author, UCLA Associate Professor and Vice Chair of Research in Neurology

The study represents some of the first validation results reported by a NIH-funded consortium of academic medical centers working to identify biomarkers associated with vascular drivers behind cognitive impairment to help inform diagnosis and treatment. The consortium, known as MarkVCID, was formed in 2016 after researchers recognized they needed a better handle on precisely how vascular brain injury was contributing to dementia.

Researchers identified signaling involved in angiogenesis as potential biomarkers, theorizing that the body may respond to damaged small blood vessels in the brain with intensified efforts to grow more. For this study, researchers focused on just one of those signals, PlGF, which has previously been associated with cerebral blood flow regulation. Data also gathered by the consortium had suggested this may be a useful biomarker for identifying patients with cognitive impairment and dementia due to vascular brain injury.

At UCLA and four other research sites, 335 patients underwent brain imaging, cognitive testing and blood collection. Researchers found those in the top quartile for PlGF measurement were three times as likely to have cognitive impairment or dementia compared to those in the bottom quartile. Every unit increase in total PlGF in the bloodstream was also associated with a 22% increase in the likelihood of having cognitive impairment and a 16% increase in the likelihood of having imaging evidence of cerebral small vessel disease.

"The addition of a blood-based biomarker that is associated with the traditional measures of vascular injury could allow a provider to be able to distinguish the patient that has Alzheimer's-predominant dementia versus a significant vascular contribution," Dr. Hinman said. "Right now it's kind of the clinician's best guess. This work can directly inform this diagnostic decision."

The research consortium is still studying whether PlGF and a bundle of other angiogenic markers in the bloodstream could help predict the risk of future cognitive decline.

Journal reference:

Hinman, J.D., et al. (2023) Placental Growth Factor is a Sensitive Biomarker for Vascular Cognitive Impairment. Alzheimer’s & Dementia.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
More than 20,000 volunteers join effort to accelerate dementia drug development